AS
FPRX

Arxis Securities’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Arxis Securities’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$267K Buy
+7,399
New +$326K 1.43% 25

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Arxis Securities's FPRX Position: Q1 2017 in Review

Arxis Securities opened a new position in Five Prime Therapeutics, Inc. (FPRX) in Q1 2017: 7,399 shares worth $267K. The stake represents 1.43% of the portfolio and ranks #25 among its holdings.

157 funds tracked by Wall St. Rank hold FPRX as of Q1 2017.

  • Arxis Securities held 7,399 shares of Five Prime Therapeutics, Inc. worth $267K as of Q1 2017.
  • Five Prime Therapeutics, Inc. was a new Arxis Securities position in Q1 2017.
  • Five Prime Therapeutics, Inc. made up 1.43% of Arxis Securities's portfolio in Q1 2017, its #25 holding.
  • 157 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2017.

Based on Arxis Securities's 13F filing for Q1 2017, filed 8 May 2017.